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Abstract
Background: Whether or not antibiotic stewardship proto-
cols based on procalcitonin levels results in cost savings 
remains unclear. Herein, our objective was to assess the 
economic impact of adopting procalcitonin testing among 
patients with suspected acute respiratory tract infection 
(ARI) from the perspective of a typical US integrated deliv-
ery network (IDN) with a 1,000,000 member catchment 
area or enrollment.
Methods: To conduct an economic evaluation of procal-
citonin testing versus usual care we built a cost-impact 
model based on patient-level meta-analysis data of ran-
domized trials. The meta-analytic data was adapted to 
the US setting by applying the meta-analytic results to US 
lengths of stay, costs, and practice patterns. We estimated 
the annual ARI visit rate for the one million member 
cohort, by setting (inpatient, ICU, outpatient) and ARI 
diagnosis.
Results: In the inpatient setting, the costs of procalcitonin-
guided compared to usual care for the one million member 
cohort was $2,083,545, compared to $2,780,322, resulting 
in net savings of nearly $700,000 to the IDN for 2014. In 
the ICU and outpatient settings, savings were $73,326 
and $5,329,824, respectively, summing up to overall net 
savings of $6,099,927 for the cohort. Results were robust 
for all ARI diagnoses. For the whole US insured popula-
tion, procalcitonin-guided care would result in $1.6 billion 
in savings annually.
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Conclusions: Our results show substantial savings asso-
ciated with procalcitonin protocols of ARI across com-
mon US treatment settings mainly by direct reduction 
in unnecessary antibiotic utilization. These results are 
robust to changes in key parameters, and the savings can 
be achieved without any negative impact on treatment 
outcomes.
Keywords: antibiotic stewardship; cost saving; economic 
evaluation; procalcitonin; respiratory infection.
Introduction
Improved diagnostics and clinical biomarkers have been 
shown to be an important part of cost-effective medical 
care in acute care settings [1–8]. Biomarkers have shown 
to be very effective in aiding diagnosis and management 
of hospital patients with suspected systemic bacterial 
infections, including community-acquired pneumonia 
(CAP) and sepsis [9–28]. Procalcitonin (PCT) is a novel 
and effective marker of assumed bacterial infections that 
safely helps guide antibiotic therapy in acute respiratory 
tract infections (ARI) and sepsis in hospitals [5, 29–40].
The use of PCT supplies caregivers with added infor-
mation, which, in principle, enables them to improve the 
selection of patients for treatment, the timing of treatment 
initiation, and the overall duration of treatment [21, 28, 32, 
33, 35, 41–47]. Insofar as caregivers change their care man-
agement and treatment strategies in response to the new 
information (relative to the usual standard course of action), 
there are implications for changes in outcomes, both in 
terms of treatment costs and health status [14, 33, 35].
There is strong evidence that PCT-guided care man-
agement results in reductions in antibiotic exposure and 
possibly costs [33, 35, 37, 38, 48–53]. For example, a com-
parative effectiveness summary report from the US Agency 
for Healthcare Research and Quality (“AHRQ”; 2012) con-
cluded that there was high strength of evidence in support 
of PCT reducing antibiotic usage, with relative reductions 
ranging from 21% to 38% [53]. According to the AHRQ 
report, some studies have shown differences in hospital 
intensive care unit (ICU) length of stay (LOS) and overall 
hospital LOS between usual care and PCT-guided care 
[48]. In most studies, the PCT-guided arm of the study was 
associated with LOS reductions between 0 and 2.5  days 
(0%–11%) [53]. Many of these studies did not show sta-
tistically significant results, although the one study with 
significant results found a 43% reduction in ICU LOS asso-
ciated with PCT testing.
Recently, Schuetz et al. (2012) performed a meta-anal-
ysis of patient-level data from 4221 adults with ARIs from 
14 clinical trials [33]. In addition to a marked reduction 
in antibiotic exposure, they found significant differences 
in treatment failure (defined as “death, hospitaliza-
tion, ARI-specific complications, recurrent or worsening 
infection, and discomfort at 30 days”) overall between 
the PCT group and the control group (19.1% and 21.9%, 
respectively). Among sub-groups, these differences were 
also observed in the emergency department (ED) and for 
patients with CAP. A meta-analysis of five studies found 
that PCT-guided treatment results in a 0.4 percentage 
point reduction in mortality [53].
Economic evaluations have shown that the clinical 
advantages associated with PCT-guided care also result 
in net savings of healthcare resources. PCT has the poten-
tial to improve the management of health care resources 
a number of ways, including: 1) reducing unnecessary 
antibiotic prescriptions and supporting improved antibi-
otic stewardship; 2) reducing hospital LOS; 3) improving 
the timing of diagnosis and treatment; and 4) improving 
the ability of clinicians to optimally match diagnosis and 
treatment [5, 34, 51, 54–60].
Based on published randomized trials of PCT-guided 
treatment in Canadian hospital intensive care units, 
Heyland et  al. conducted a cost-minimization analysis 
based on the costs of PCT testing and antibiotic acquisition 
and administration [51]. PCT-guided strategies were asso-
ciated with a significant reduction in antibiotic use, and 
PCT-guided care was not associated with any differences 
in hospital mortality. Michaelidis et al. assessed the cost-
effectiveness of PCT-guided antibiotic therapy (vs. usual 
care) in outpatient management of ARI in adults, based on 
the results of two published European clinical trials [56]. 
In the cohort including all adult ARIs judged to require 
antibiotics by their physicians, the costs of PCT-guided 
care was $31 per antibiotic prescription safely avoided and 
the likelihood of PCT use being favored (compared to usual 
care) was 58.4% in a probabilistic sensitivity analysis – an 
amount well below the willingness-to-pay. PCT-guided 
care also appears to have cost-saving effects in sepsis care. 
Deliberato et al. assessed patients with suspected sepsis, 
severe sepsis, or septic shock in a hospital ICU, and found 
that in the PCT-guided group median antibiotic duration 
was 9 days vs. 13 days in the non-PCT group [50].
The existing economic literature on PCT has several 
important gaps. First, none of the existing studies 
examine the cumulative economic effects of PCT in all 
of the clinical settings in which it can be employed (i.e., 
hospital wards, hospital ICUs, and outpatient clinics and 
EDs). Second, the existing economic studies do not make 
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full use of recent meta-analyses of clinical trials, such as 
Schuetz et al. [33, 34]. Third, none of the economic studies 
pertain to the US market. Our study fills these three gaps in 
the current PCT economic literature by examining effects 
across all the different clinical settings in which PCT may 
be used, making use of recent meta-analytic studies of 
PCT clinical effectiveness, and focusing on the US health 
system, including US cost structure and practice patterns.
The objective of this study is to assess the clinical 
and economic impact of adopting PCT testing and moni-
toring versus usual care among patients with suspected 
lower respiratory tract infection from the perspective of 
a typical US integrated delivery network (IDN) or payer 
with a 1,000,000 member catchment area or enrollment. 
Our study fills the aforementioned gaps in the current PCT 
economic literature by examining effects across all the dif-
ferent clinical settings in which PCT may be used, making 
use of recent meta-analytic studies of PCT clinical effec-
tiveness, and focusing on the US health system.
Materials and methods
For this analysis we used patient-level data from a recently published 
comprehensive meta-analysis of available clinical trial data [33]. The 
protocol for this meta-analysis is published in the Cochrane Library 
[61]. In brief, 4221 patients with different types of respiratory infec-
tions of varying severity, including upper respiratory infections, 
acute bronchitis (AB), exacerbation of chronic obstructive pulmo-
nary disease (ECOPD), CAP and ventilator-associated pneumonia 
(VAP) from 14 randomized trials were included in this analysis. The 
main variables used from the meta-analytic database were days of 
antibiotic exposure by diagnosis and setting.
To conduct the economic evaluation of PCT testing and moni-
toring versus usual care we built a cost-impact model in MS Excel®. 
The patient population in this study is patients with suspected ARI 
infection diagnoses seen in one of three settings: inpatient hospital 
setting (not in the ICU); hospital ICU; outpatient clinic or ED based 
on the meta-analysis data. We first estimated the annual ARI visit 
rate per 100,000 population, by setting and diagnosis (Table 1). The 
numerator (number of visits) is based on recent US national inpa-
tient and outpatient population surveys [63, 64]. Rates were then 
calculated based on population estimates from the US Census. The 
expected number of annual visits was then estimated by multiplying 
plan size by the estimated rate (Table 1).
We modeled PCT testing differently for each treatment setting. 
For inpatient stays we assumed that there would be an initial PCT test 
upon initial presentation (e.g., ED admitted to ward or ICU) and sub-
sequent monitoring tests every other day until discharge. For partial 
days we rounded to the nearest whole day of stay (i.e., 5.2 LOS – tests 
on Days 1, 3 and 5). Outpatient care (e.g., ED discharged home, hos-
pital outpatient or office visit) assumed a single PCT test to support 
antibiotic initiation.
Cohort patients are assumed to enter the “usual care” arm or the 
PCT arm. To model the effect of routine PCT utilization we compare 
the same number of patients in each treatment protocol. The treat-
ment algorithm is adapted to setting of care as described above. For 
example, we assume no PCT follow-up monitoring in the outpatient 
setting. Based on the clinical studies included in the meta-analytic 
data, the costs and outcomes of each ARI episode is assessed over 
a 30-day period. Total costs and events are annualized based on the 
incidence of each condition and likelihood of treatment success and 
intensity. Depending on which arm of the decision tree a patient trav-
els, the costs of antibiotic therapy and monitoring, PCT testing, total 
number of patients on antibiotic therapy, and total days of antibiotic 
Table 1 Acute lower respiratory infection rates and estimated number of annual cases in a typical US integrated health system and patient-
level mean antibiotic initiation, by treatment protocol, setting and diagnosis.
Setting/
diagnosis
  No. of annual 
cases per 1 
million insureda
 
 
Mean antibiotic initiation rateb
PCT  Usual care  % Point difference PCT vs. UCc
Hospital Ward/ED  5006  75.7% (0.43)  89.5% (0.31)  –15.5
 AB   350  29.4% (0.46)  65.3% (0.48)  –55.0
 CAPd   2960  93.0% (0.26)  99.7% (0.06)  –6.7
 ECOPD   1697  50.0% (0.50)  74.1% (0.44)  –32.5
Hospital ICU   528  99.7% (0.06)  100.0%  –0.3
 CAPe   522  100.0%  100.0%  0.0
 VAP/HAPf   5  99.4% (0.08)  100.0%  –0.6
Clinic/ED   53,651  36.2% (0.48)  69.3% (0.46)  –47.8
 AB   22,378  22.7% (0.42)  65.7% (0.48)  –65.5
 CAP   14,999  75.4% (0.43)  97.0% (0.17)  –22.2
 ECOPD   16,275  36.5% (0.49)  67.9% (0.47)  –46.2
See text. aBased on data from the US Census [62], US HCUP [63] and US NAMCS-NHAMCS [64], per 1,000,000 insured lives in a US inte-
grated delivery system; bStandard deviations in brackets; cpercentage point difference; dassumes 85% of all CAP discharges are treated 
in hospital ward; 100% of COPD and AB cases treated in ward; eassumes 15% of all CAP discharges are admitted to ICU; f100% of VAP/HAP 
admitted to hospital ICU. AB, acute bronchitis; CAP, community acquired pneumonia; ECOPD, exacerbations of chronic obstructive pulmo-
nary disease; UC, usual care; VAP/HAP, ventilator-associated pneumonia, also referred to as hospital-acquired pneumonia.
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exposure are summed. Differences in antibiotic initiation rates, anti-
biotic therapy days among those initiated on antibiotic therapy and 
percent successfully treated are based on the Schuetz et  al. meta-
analysis [33] (Tables 1 and 2).
Baseline US hospitalization LOS and overall costs of care for 
selected ARI inpatient care are shown in Table 3, based on an analy-
sis of the US Health Care Cost and Utilization Project (HCUP) National 
Inpatient Sample [63]. The table also shows weighted mean costs per 
episode for these diagnoses; these data are provided as background 
and not used in subsequent analyses. In the model, we assumed that 
the mean baseline number of antibiotic days corresponds to the aver-
age LOS for a typical hospitalization (Table 3).
The perspective of the model is that of a US IDN or payer assum-
ing full or partial financial risk for all sites of care. We therefore 
developed the cost-impact model to capture the current burden of 
managing suspected ARI and the potential impact of implementing 
routine PCT testing. The model describes the expected annual rate of 
visits, site of service and diagnosis mix across the plans catchment 
area or enrolled population. The cohort enters the model at risk for 
an ARI episode and may present for care at one of three sites of ser-
vice described earlier. The likelihood of presentation at each site and 
with each diagnosis is based on US annual incidence rates [63, 64].
The primary outcome measure was total antibiotic-related costs 
by setting (hospital ward/ED, hospital ICU, or clinic/ED) attribut-
able to PCT-guided care versus usual care. Daily costs of antibiotic 
therapy for inpatient stays were estimated based on typical daily 
dosage multiplied by the wholesale acquisition cost of each drug. 
Typical dosages and mix of expected therapy were derived from 
published clinical treatment guidelines [65–75]. Guidelines outline 
multiple treatment options and patients may require more than one 
antibiotic administered concurrently. In these cases we estimated the 
weighted average cost of a prototypical representative of a given drug 
class weighted by the likelihood of receiving multiple drugs during 
a typical stay (Table 4). Daily cost of antibiotic administration was 
estimated based on a recently published cost analysis [76].
The cost of PCT testing (HCPCS 84145) was estimated based on 
the average Medicare laboratory payment in 2014. Physician time 
Table 2 Patient-level mean antibiotic days among those initiated on antibiotic treatment, and percent successfully treated: by treatment 
protocol, setting and diagnosis.
Setting/
diagnosis
 
 
Mean antibiotic daysa 
 
Successfully treated patientsa
PCT  Usual care 
 
Percent difference
PCT vs. UCb
PCT  Usual care 
 
Percent difference
PCT vs. UCa
Hospital Ward/ED   7.76 (5.02)  10.73 (5.58)  –27.7%  82.8% (0.38)  83.3% (0.37)  –0.6
 AB   4.50 (3.68)  7.10 (3.86)  –36.6%  82.4% (0.38)  84.0% (0.37)  –2.0
 CAP   8.10 (5.09)  11.61 (5.47)  –30.3%  80.8% (0.39)  81.7% (0.39)  –1.1
 ECOPD   6.81 (4.29)  8.33 (3.68)  –18.2%  87.3% (0.33)  87.2% (0.33)  0.1
ICU   10.52 (6.86)  13.73 (7.27)  –23.4%  80.1% (0.40)  76.2% (0.43)  5.2
 CAP   9.01 (5.65)  13.44 (7.49)  –33.0%  62.3% (0.49)  57.8% (0.50)  7.8
 VAP/HAP   11.78 (7.51)  14.00 (7.07)  –15.8%  94.9% (0.22)  92.7% (0.26)  2.4
Clinic/ED   6.27 (3.18)  7.86 (3.32)  –20.2%  75.1% (0.43)  75.4% (0.43)  –0.5
 AB   7.66 (3.02)  7.19 (2.63)  6.5%  72.9% (0.45)  75.8% (0.43)  –3.8
 CAP   5.99 (3.34)  8.52 (3.95)  –29.6%  85.1% (0.36)  87.0% (0.34)  –2.1
 ECOPD   5.16 (2.24)  8.83 (3.56)  –41.6%  82.7% (0.38)  79.2% (0.41)  4.3
See text. aStandard deviations in brackets; bPercent difference. AB, acute bronchitis; CAP, community acquired pneumonia; ECOPD, exacer-
bations of chronic obstructive pulmonary disease; UC, usual care; VAP/HAP, ventilator-associated pneumonia, also referred to as hospital-
acquired pneumonia.
Table 3 National average length of stay and inpatient costs among 
ARI patients in the US, 2014.
Condition/
disease
  ICD9 code 
ranges
  Mean 
length of 
hospital 
stay 
(2011)a
  Mean total 
hospital 
costs per 
episode 
(2014)b
  Mean total 
hospital 
costs 
per day 
(2014)c
AB   466.0, 466.19  3.0  $5086  $1695
CAP   485, 486, 
481,482, 483
  5.1  $9925  $1946
ECOPD   491.21–491.21  4.4  $8202  $1864
HAP/VAP   997.31  13.0  $34,481  $2652
Meand     5.9  $12,790  $2067
aBased on calculations using the 2011 public-use inpatient sample 
data from HCUP; bBased on 2011 HCUP calculations, trended forward 
to 2014 using the consumer price index inflation adjuster; cTotal 
hospital costs per episode divided by mean length of stay per 
episode; dWeighted by case volume. AB, acute bronchitis; CAP, 
community acquired pneumonia; ECOPD, exacerbations of chronic 
obstructive pulmonary disease; VAP/HAP, ventilator-associated 
pneumonia, also referred to as hospital-acquired pneumonia.
associated with interpreting the PCT test was not included in the 
model because the associated costs have been found to be negligi-
ble [56]. Outpatient clinic treatment costs were estimated based on a 
recent study that examined the economic impact of antibiotic utiliza-
tion incorporating estimates of the cost of initial antibiotic therapy 
but also induced follow-on costs associated with a new antibiotic 
prescription [56]. Costs are expressed per episode and were converted 
to per day costs using a typical average length of antibiotic therapy.
Daily costs attributable to antibiotic resistance were derived 
from a recent economic study of antibiotic use in the clinic setting 
[56]. This analysis used recent US national estimates of excess cost 
attributed to resistance and derived antibiotic cost per prescription 
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IDN. The ICU setting also resulted in savings ($73,326), but 
the savings were smaller than other settings because US 
protocols heavily favor empirical prescribing of antibiot-
ics in hospital ICUs [73].
The outpatient clinic and ED are where PCT has 
its largest effect. In the clinic and ED, the costs of PCT-
guided care for the cohort was $5,624,532, compared to 
$10,954,356, resulting in net savings of $5,329,824 to the 
IDN. Across all three settings, PCT-guided care is associ-
ated with a total cost of $8,033,338 for the one million 
member cohort, compared to $14,133,265 for the usual 
care group, resulting in an overall net savings to the IDN 
of $6,099,927.
Sensitivity analysis
To test the impact of model assumptions we conducted a 
series of one-way deterministic sensitivity analyses. Key 
model parameters were increased or decreased by 20% to 
assess the effect of each assumption on model results. The 
key output measure was the total cost difference across all 
three clinical settings (–$6,099,927). We conducted analy-
ses on the following model inputs: 1) percentage reduc-
tion in antibiotic days in the PCT group; 2) daily cost of 
antibiotics and monitoring; 3) type of PCT protocol (i.e., 
frequency of testing) followed in hospital settings; and 4) 
antibiotic resistance costs.
Model results are most sensitive to estimates of 
the daily cost of antibiotic treatment, ranging from 
$4.8 million savings to $7.4 million savings. Percent-
age reduction in antibiotic days in the PCT group is the 
next most important factor, with savings ranging from 
$5.6 million at the lower bound to $6.7 million at the 
upper bound of the range (Figure 1). The costs of antibi-
otic resistance had only a modest impact on the results, 
ranging from $5.8 million to $6.3 million at the lower 
and upper bounds, respectively. PCT test frequency 
among hospitalized patients had the smallest impact, 
ranging from $5.7 million in savings if the test is admin-
istered once a day versus $6.1 million in the base case 
protocol where testing was assumed to occur every 
other day (Figure 1).
We also tested the sensitivity of the model with respect 
to baseline antibiotic initiation rates. For this analysis we 
focused on CAP, because in the US the vast majority of 
CAP patients are started on antibiotics in all three settings 
(see Table 5). However, the sensitivity analysis showed 
that PCT-guided care resulted in savings even with CAP 
antibiotic initiation rates as low as 65%, holding all other 
variables constant.
Table 4 Cost parameters by setting and diagnosis.
Diagnosis/setting/measure   Value
Hospital ward/ED  
 Antibiotic cost, per day  
  Acute bronchitis   $25.13
  CAP   $73.18
  ECOPD   $49.07
Hospital ICU  
 Antibiotic cost, per day  
  CAP   $73.18
  HAP/VAP   $362.22
 Antibiotic administration cost, per daya   $59.39
Clinic/EDb  
 Initial antibiotic prescription cost, per day 
  AB   $9.10
  CAP   $16.35
  ECOPD   $9.10
 Follow-up costs, per day  
  AB   $14.67
  CAP   $32.53
  ECOPD   $14.67
PCT Cost per testc   $49.38
See text. aBased on Van Zanten et al. [76]; bPer episode costs, 
including induced follow-on costs such as office visits (based on 
Monte et al. [77]; cCMS HCPCS 84145 – National Medicare Midpoint 
2014. AB, acute bronchitis; CAP, community acquired pneumonia; 
ECOPD, exacerbations of chronic obstructive pulmonary disease; 
VAP/HAP, ventilator-associated pneumonia, also referred to as 
hospital-acquired pneumonia.
and allocated costs based on the volume of antibiotic prescriptions 
annually for ARI in the US. The estimated cost per prescription was 
$43. We estimated the daily costs of antibiotic resistance by dividing 
the cost per prescription by the average duration (number of days) of 
a typical antibiotic prescription.
We conducted one-way deterministic sensitivity analyses on 
selected measures, including: 1) percentage reduction in antibiotic 
days in the PCT group; 2) daily cost of antibiotics and monitoring; 3) 
type of PCT protocol followed in hospital settings; and 4) antibiotic 
resistance costs.
Results
Overall results
Results of the cost impact model by clinical setting are 
shown in Table 5. In all three settings, PCT-guided care 
was shown to be cost saving across all treatment settings 
and diagnoses. In the hospital ward and ED, the costs of 
PCT-guided care for the one million member cohort was 
$2,083,545, compared to $2,780,332 for the usual care 
group, resulting in net savings of nearly $700,000 to the 
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As the model was most sensitive to the daily costs of 
antibiotics, we also conducted a break-even analysis. For 
this analysis we considered only the direct cost impact 
comparing cost of PCT testing to cost savings associated 
with reduced antibiotic use. Our analysis suggests that 
PCT testing would maintain cost savings even when anti-
biotic treatment costs are assumed to be only 22% of our 
base model assumption. Put differently, this suggests 
that daily antibiotic costs could be nearly one-fifth of our 
assumed value for a strategy of PCT testing to remain at 
least cost neutral to a typical US IDN.
Discussion
Our results show substantial savings associated with the 
use of PCT to guide antibiotic treatment of ARI across 
common US treatment settings. Across all three settings, 
PCT-guided care is associated with a total of $5,887,535, 
compared to $12,296,714 for usual care, resulting in an 
overall net savings to the IDN of $6,099,927 based on 
a population of 1,000,000 insured lives. These results 
are robust to changes in key parameters. In the sensitiv-
ity analysis, most parameter variations resulted in only 
Table 5 IDN budget impact of PCT versus usual care in treatment of ARI in US hospitals, by setting, 2014.
Protocol/diagnosis   Na  Initiated 
on ABxb
  Reduction 
days ABx
  PCT Testing 
Costc
  Number of 
ABx days
  Daily ABx 
costs
  ABx resistance 
cost
  Total cost of 
ABx
Hospital ward/emergency departmentd
 PCT                
  AB   350  29.4%  –36.6%   $5077  195  $85  $1173  $22,769
  CAP   2960  93.0%  –30.3%   $271,797  9783  $133  $58,698  $1,627,391
  ECOPD   1697  50.0%  –18.2%   $83,793  3054  $108  $18,326  $433,385
  Total   5006        13,033    $78,197  $2,083,545
 Usual care                
  AB   350  65.3%  NA   $0  685  $85  $4111  $62,023
  CAP   2960  99.7%  NA   $0  15,049  $133  $90,294  $2,085,285
  ECOPD   1697  74.1%  NA   $0  5531  $108  $33,184  $633,013
  Total   5006        21,265    $127,589  $2,780,322
PCT Value to IDN (Hospital/ED)           –8232    –$49,392  –$696,777
Hospital ICUd
 PCT                
  CAP   522  100.0%  –33.0%   $51,586  1786  $133  $10,716  $299,064
  VAP/HAP   5  99.4%  –15.8%   $1560  58  $422  $346  $26,197
  Total   528        1844    $11,062  $325,261
 Usual care                
  CAP   522  100.0%  NA   $0  2664  $133  $15,983  $369,126
  VAP/HAP   5  100.0%  NA   $0  69  $422  $413  $29,462
  Total   528        2733    $16,397  $398,588
PCT value to IDN (Hospital ICU)           –889    –$5335  –$73,326
Clinic/ED
 PCT                
  AB   22,378  22.7%  6.5%   $250,312  37,790  $24  $226,739  $1,375,260
  CAP   14,999  75.4%  –29.6%   $558,725  55,751  $49  $334,508  $3,618,678
  ECOPD   16,275  22.7%  –41.6%   $182,039  15,068  $24  $90,409  $630,595
  Total   53,651        108,609    $651,655  $5,624,532
 Usual care                
  AB   22,378  65.7%  NA   $0  102,918  $24  $617,509  $3,063,725
  CAP   14,999  97.0%  NA   $0  101,796  $49  $610,773  $5,587,120
  ECOPD   16,275  67.9%  NA   $0  77,381  $24  $464,284  $2,303,511
  Total   53,651        282,094    $1,692,566  $10,954,356
PCT value to IDN (Clinic/ED)           –173,485    –$1,040,910  –$5,329,824
Total PCT value to IDN           –182,606    –$1,095,637  –$6,099,927
See text & Table 1. aSee Table 1; cohorts based on 1,000,000 covered lives in a US integrated delivery system; bBased on Schuetz et al. 
[33, 34]; cSee Table 4; assumes one test on the first day of admission and follow-up tests every other day while in hospital in the PCT cohort; 
dincludes $59 per day antibiotic administration costs (see Table 4). AB, acute bronchitis; ABx, antibiotics; CAP, community acquired pneu-
monia; ECOPD, exacerbations of chronic obstructive pulmonary disease; VAP/HAP, ventilator-associated pneumonia, also referred to as 
hospital-acquired pneumonia.
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small changes in total savings. The results were sensi-
tive to daily antibiotic treatment costs, which are likely to 
vary to some degree regionally and among different IDNs, 
but the  ± 20% variation still results in savings of at least 
$5 million to the IDN.
These results are similar to those of Heyland et  al. 
and Michaelidis et  al., both of which found substantial 
savings attributable to PCT-guided treatment protocols 
[51, 56]. Interesting, those studies reached similar conclu-
sions but relied on methods substantially different than 
ours. This adds to the robustness of the results.
We modeled the cost differential that would be real-
ized within a US IDN with 1,000,000 covered lives. In the 
US, there are 262,246,800 individuals with some form of 
health insurance. Extrapolating to this larger popula-
tion, based on our model PCT-guided care would result 
in approximately $1.6 billion in savings nationally. If we 
assume that, to some extent, the recently passed Afford-
able Care Act (ACA) in the US will extend insurance to the 
entire population, the total savings attributable to PCT-
guided care would be about $1.9 billion nationally.
It is important to emphasize that the savings asso-
ciated with PCT-guided care is not associated with any 
meaningful differences in quality, which has been a con-
sistent finding of clinical effectiveness studies of PCT to 
date [5, 30, 34, 38, 52, 78, 79]. Moreover, our calculations 
take into account the costs of the tests and the adminis-
tration of the tests. The implication is that the savings 
are “real” savings to an IDN – the tests more than pay for 
themselves without negatively affecting treatment out-
comes. In addition, it is important to stress that our esti-
mate of the daily costs of antibiotic resistance is likely very 
conservative, as increasingly the literature and reports on 
–$8,000,000
–$7,000,000
–$6,000,000
–$5,000,000
–$4,000,000
–$3,000,000
–$2,000,000
–$1,000,000
$0
Hospital
Ward/ED Hospital ICU Clinic/ED Total IDN value
Figure 1 IDN budget impact and confidence intervals based on 
days of antibiotic exposure: PCT versus usual care in treatment of 
ARI in US hospitals, by setting, 2014.
antibiotic resistance suggests that the amount might be 
substantially higher [80].
Previous studies have not directly assessed differ-
ences in outcomes in quality of life and functioning dimen-
sions following PCT-guided treatment [53]. However, given 
that time spent in-hospital generally is associated with a 
lower level of health-related quality of life (HRQoL) than 
time spent out of hospital, PCT-guided treatment would 
be likely to translate into improvements in HRQoL if it 
reduces hospital LOS. Similarly, adverse effects of antibi-
otic treatment may reduce HRQoL; thus the reduction in 
antibiotic exposure resulting from PCT-guided treatment 
also may translate into improvements in HRQoL.
A key assumption is whether PCT testing correlates 
with actual change in care management; that is, to what 
extent do physicians react to the results of PCT testing? 
Put differently, to what extent do physicians weigh PCT 
results versus other forms of clinical information? In 
economic models of diagnostics, a common challenge 
is determining whether the existence of new or differ-
ent information actually changes physician behavior. 
In a randomized study design, where patients are ran-
domized to PCT-guided care versus usual care, this 
problem may not be too serious because, in theory, any 
differences in endpoints can be attributed to the inter-
vention. However, the extent of this causal relationship 
is dependent on the overall quality of the study design. 
Moreover, any given hospital could argue that their phy-
sicians and care management teams “tend to do things 
differently.” For example, Dusemund et  al. found con-
siderable variation in how physicians react to PCT test 
results [35].
Another potential limitation of our study is that the 
meta-analytic data used pertain primarily to European 
settings. The model was designed to account for these dif-
ferences in two ways – by using US data on LOS, utiliza-
tion rates, and costs, and by applying US practice patterns 
as reflected in clinical practice guidelines. Although this 
approach is likely to provide a reasonable approximation 
of the cost impact of PCT in US clinical settings, a more 
definitive approach would have been to use US trial data 
analogous to the meta-analytic data compiled by Schuetz 
et al. Such data, however, were not available for this study.
Conclusions
Our results show substantial savings associated with 
the use of PCT to guide antibiotic treatment of ARI in 
common US treatment settings. Across all three settings, 
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PCT-guided care is associated with net savings ranging 
from $73,326 in the ICU to  > $5 million in the outpatient 
clinic and ED setting, for total savings to the IDN of more 
than $6 million. These results are robust to changes in key 
parameters, and the savings can be achieved without any 
negative impact on treatment outcomes.
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